Drug comparisons
Eptinezumab vs Fremanezumab
Eptinezumab (Vyepti) and Fremanezumab (Ajovy) are CGRP-targeted mAbs for migraine prevention. Eptinezumab IV q3mo, Fremanezumab SC q1mo/q3mo. Similar safety and efficacy; choice based on dosing preference.
No comparison dimensions are available for this page.
Clinical context
Migraine patients seeking CGRP monoclonal antibody therapy often compare Eptinezumab and Fremanezumab to choose the optimal preventive option.
Bottom line
Both Eptinezumab and Fremanezumab are effective CGRP inhibitors for migraine prevention, but the better option depends on individual factors like administration route and frequency.
All medication comparisons